MONARCH 3: Abemaciclib as initial therapy for patients with HR+, HER2-advanced breast cancer - Results from the preplanned final PFS analysis

被引：1

作者：

Goetz, Matthew P. ^{[1
]}

Martin, Miguel ^{[2
,3
]}

Di Leo, Angelo ^{[4
]}

Im, Seock-Ah ^{[5
]}

Awada, Ahmad ^{[6
]}

Forrester, Tammy ^{[7
]}

Frenzel, Martin ^{[7
]}

Cox, Joanne ^{[8
]}

Barriga, Susana ^{[9
]}

Toi, Masakazu ^{[10
]}

Iwata, Hiroji ^{[11
]}

Johnston, Stephen ^{[12
]}

机构：

[1] Mayo Clin, Rochester, MN USA

[2] Geicam, Inst Invest Sanitaria Gregorio Maranon, Ciberonc, Madrid, Spain

[3] Univ Complutense, Madrid, Spain

[4] Hosp Prato, Prato, Italy

[5] Seoul Natl Univ, Seoul Natl Univ Hosp, Coll Med, Seoul, South Korea

[6] Jules Bordet Inst, Brussels, Belgium

[7] Eli Lilly & Co, Indianapolis, IN 46285 USA

[8] Eli Lilly & Co, Windlesham, Surrey, England

[9] Eli Lilly & Co, Madrid, Spain

[10] Kyoto Univ, Kyoto, Japan

[11] Aichi Canc Ctr Hosp, Nagoya, Aichi, Japan

[12] Royal Marsden NHS Fdn Trust, London, England

来源：

关键词：

D O I：

10.1158/1538-7445.AM2018-CT040

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

CT040

引用

页数：2